2024
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel
Gandhi R, Landovitz R, Sax P, Smith D, Springer S, Günthard H, Thompson M, Bedimo R, Benson C, Buchbinder S, Crabtree-Ramirez B, del Rio C, Eaton E, Eron J, Hoy J, Lehmann C, Molina J, Jacobsen D, Saag M. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel. JAMA 2024, 333 PMID: 39616604, DOI: 10.1001/jama.2024.24543.Peer-Reviewed Original ResearchAntiretroviral drugsHIV preventionSubstance use disordersLong-acting injectable therapyManagement of HIV infectionIntegrase strand transfer inhibitorsNucleotide reverse transcriptase inhibitorsStrand transfer inhibitorsSexually transmitted infectionsPeer-reviewed scientific conferencesDaily oral medicationReverse transcriptase inhibitorsLong-acting medicationsManagement of substance use disordersPrevention of HIVCardiovascular disease preventionTreating substance use disordersVirological failureAntiretroviral therapyHIV acquisitionHIV infectionHIV exposureInjection therapyDaily therapyLaboratory monitoring
2023
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Gandhi R, Bedimo R, Hoy J, Landovitz R, Smith D, Eaton E, Lehmann C, Springer S, Sax P, Thompson M, Benson C, Buchbinder S, del Rio C, Eron J, Günthard H, Molina J, Jacobsen D, Saag M. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA 2023, 329: 63-84. PMID: 36454551, DOI: 10.1001/jama.2022.22246.Peer-Reviewed Original ResearchConceptsPrevention of HIVAntiretroviral therapySubstance use disordersAntiretroviral drugsUse disordersCertain antiretroviral medicationsDaily oral regimenInhibitor-containing regimensManagement of comorbiditiesMonkeypox virus infectionDiagnosis of HIVSARS-CoV-2 pandemicCare of peopleGlobal health emergencyInitial therapyOral regimenAdherence supportMetabolic complicationsPreexposure prophylaxisViral suppressionAntiretroviral medicationsOral medicationsHIV infectionLaboratory monitoringInjectable therapies
2021
Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence
Schultheis A, Sanchez M, Pedersen S, Kyriakides T, Ho YC, Kluger Y, Springer SA. Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence. Contemporary Clinical Trials Communications 2021, 24: 100866. PMID: 34825103, PMCID: PMC8605182, DOI: 10.1016/j.conctc.2021.100866.Peer-Reviewed Original ResearchOpioid use disorderHIV-1 persistenceHIV persistenceCohort studyHIV infectionMedication treatmentLimited bloodUse disordersProviral landscapeDSM-5 opioid-use disordersExtended-release naltrexoneProspective cohort studyHIV-1 expressionPartial agonist buprenorphineLongitudinal studyHIV continuumMonth 3Clonal expansion dynamicsMOUDDifferential biological effectsStudy participantsHIVMolecular virologyBloodBuprenorphineDesign and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder
Biondi BE, Mohanty S, Vander Wyk BV, Montgomery RR, Shaw AC, Springer SA. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemporary Clinical Trials Communications 2021, 21: 100704. PMID: 33490708, PMCID: PMC7807244, DOI: 10.1016/j.conctc.2021.100704.Peer-Reviewed Original ResearchOpioid use disorderProspective cohort studyHIV infectionCohort studyMedication treatmentUse disordersDSM-5 opioid-use disordersLongitudinal studyBiological effectsHIV continuumMonth 6Immune responseDifferential biological effectsMOUDHIVSystems biology approachInfectionTreatmentDSM-5DisordersPersonsBiology approachMedicationsBuprenorphineMethadone
2020
Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose.
Strathdee SA, Kuo I, El-Bassel N, Hodder S, Smith LR, Springer SA. Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose. AIDS 2020, 34: 1997-2005. PMID: 32826391, PMCID: PMC7606503, DOI: 10.1097/qad.0000000000002673.Peer-Reviewed Original ResearchConceptsHIV outbreakRecent HIV outbreaksEpidemiology of HIVEvidence-based interventionsOpioid disordersHIV infectionTreatment cascadeEvidence-based responsesHIV epidemicOpioid epidemicHIV preventionPrescription opiatesHIVPWIDSynthetic opioidsDrugsPublic healthInfectionPreventionHigher proportionUnited StatesEpidemicOutbreakEditorial reviewRelentless cycle
2018
Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative
Beckwith CG, Kuo I, Fredericksen RJ, Brinkley-Rubinstein L, Cunningham WE, Springer SA, Loeliger KB, Franks J, Christopoulos K, Lorvick J, Kahana SY, Young R, Seal DW, Zawitz C, Delaney JA, Crane HM, Biggs ML. Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative. PLOS ONE 2018, 13: e0197730. PMID: 29787580, PMCID: PMC5963777, DOI: 10.1371/journal.pone.0197730.Peer-Reviewed Original ResearchConceptsHIV care continuum outcomesCare continuum outcomesContinuum outcomesTransgender womenCisgender menViral suppressionHIV riskCondomless sexRisk behaviorsSexual partnersExchange sexMean percent adherenceCrack/cocaineMultiple sexual partnersRisk reduction interventionsHigh rateHIV continuumHIV infectionPercent adherenceCare outcomesHIVReduction interventionsCocaine useDrug abuseCJ system
2017
Cohort profile: seek, test, treat and retain United States criminal justice cohort
Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort profile: seek, test, treat and retain United States criminal justice cohort. Substance Abuse Treatment, Prevention, And Policy 2017, 12: 24. PMID: 28511680, PMCID: PMC5433052, DOI: 10.1186/s13011-017-0107-4.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsTreatment cascadeViral loadHIV RNA viral loadCD4 T-cell countRisk behaviorsSubstance useT-cell countsHepatitis C infectionRNA viral loadInjection drug useHealth Related QualityHIV treatment cascadeUnprotected sexual intercourseHealth care accessRecent polysubstance useC infectionViral suppressionHIV diagnosisHIV infectionMedian ageRelated qualityCriminal justice involvementART treatmentCohort members
2016
Erratum to “Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system” [Drug Alcohol Depend. 157 (2015) 158–165]
Springer S, Brown S, Di Paola A. Erratum to “Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system” [Drug Alcohol Depend. 157 (2015) 158–165]. Drug And Alcohol Dependence 2016, 161: 372. PMID: 28463553, PMCID: PMC4871258, DOI: 10.1016/j.drugalcdep.2016.02.009.Peer-Reviewed Original Research
2015
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system
Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug And Alcohol Dependence 2015, 157: 158-165. PMID: 26560326, PMCID: PMC4675147, DOI: 10.1016/j.drugalcdep.2015.10.023.Peer-Reviewed Original ResearchConceptsAlcohol use disorderExtended-release naltrexoneOpioid use disorderXR-NTXUse disordersHIV diseaseFirst injectionDouble-blind placebo-controlled randomized trialSecond injectionPlacebo-controlled randomized trialSubstance use disordersMultivariate regression analysisTreatment of alcoholCorrelates of retentionAntiretroviral therapyStudy drugHIV infectionRandomized trialsUrine testsUrine screensEligible personsDays of releaseHazardous drinkingCocaine useDemographic featuresDrug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective
Springer SA, Larney S, Alam-mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: s155-s161. PMID: 25978482, PMCID: PMC4443704, DOI: 10.1097/qai.0000000000000637.Peer-Reviewed Original ResearchConceptsMedication-assisted therapyDrug treatmentAntiretroviral therapyHIV transmission riskNew HIV infectionsHarm reduction servicesSubstance use disordersPoor treatment accessImplementation of interventionsOpioid useHIV infectionEvidence-based practiceHIV preventionOpioid addictionTreatment accessUse disordersReduction servicesSexual riskTransmission riskTherapyWomenTreatmentDrugsImpressive lackSignificant reduction
2011
HIV-Related Research in Correctional Populations: Now is the Time
Rich JD, Wohl DA, Beckwith CG, Spaulding AC, Lepp NE, Baillargeon J, Gardner A, Avery A, Altice FL, Springer S, On behalf of the Centers for AIDS Research—Collaboration on HIV in Corrections (CFAR-CHIC) Working Group. HIV-Related Research in Correctional Populations: Now is the Time. Current HIV/AIDS Reports 2011, 8: 288. PMID: 21904902, PMCID: PMC3208731, DOI: 10.1007/s11904-011-0095-3.Peer-Reviewed Original ResearchConceptsPrevention of HIVTransmission of HIVMental health disordersAcademic medical centerIllicit drug useEpidemic of incarcerationHIV-Related ResearchAntiretroviral therapyHIV infectionHIV transmissionMedical CenterHIVHealth disordersDrug useRisk behaviorsAIDS researchSubstance useSubstantial proportionNational InstituteRecent evidenceIncarcerated populationsPublic healthHealthCorrectional populationsPopulation
2007
Improving the Care for HIV-Infected Prisoners: An Integrated Prison-Release Health Model
Springer S, Altice F. Improving the Care for HIV-Infected Prisoners: An Integrated Prison-Release Health Model. 2007, 535-555. DOI: 10.1007/978-0-387-71695-4_30.Peer-Reviewed Original ResearchAntiretroviral therapyHIV careViral loadHIV-1 RNA levelsCommunity settingsActive antiretroviral therapyComorbid medical conditionsHuman Services guidelinesNormal life expectancySerious psychiatric illnessSubstance use disordersHIV/AIDSDepartment of HealthHAART regimensCD4 countHIV diseaseHIV infectionChronic conditionsPsychiatric illnessMedical conditionsGeneral populationHealth care institutionsUse disordersHIVViral replication
2005
Correlates of HIV infection among incarcerated women: Implications for improving detection of HIV infection
Altice FL, Marinovich A, Khoshnood K, Blankenship KM, Springer SA, Selwyn PA. Correlates of HIV infection among incarcerated women: Implications for improving detection of HIV infection. Journal Of Urban Health 2005, 82: 312-326. PMID: 15872190, PMCID: PMC3456574, DOI: 10.1093/jurban/jti055.Peer-Reviewed Original ResearchConceptsHIV infectionHIV testingHigh HIV prevalence areasMultiple logistic regression analysisWidespread HIV testingGenital herpes infectionVoluntary HIV counselingHIV prevalence areasInjection drug usePrevalence of HIVAnonymous HIV testingRisk behavior informationHigh-risk groupRapid serologic testsHIV risk behaviorsLogistic regression analysisPublic health benefitsIncarcerated womenHIV seroprevalenceHerpes infectionHIV counselingHIV serosurveyLaboratory markersIndependent correlatesRisk factors18 Management of HIVIAIDS in Correctional Settings
Altice F, Springer S. 18 Management of HIVIAIDS in Correctional Settings. 2005, 449-487. DOI: 10.1016/b978-012465271-2/50021-2.Peer-Reviewed Original ResearchClean injection equipmentHepatitis virus BHepatitis virus CPrevalence of HIVSelf-administered therapyArea of HIVSyringe exchange programsGeneral U.S. populationCorrectional settingsObserved therapyHIV infectionHIV medicationsComorbid conditionsMethadone maintenanceOwn medicationsSyringe exchangeNew casesVirus CCommunity settingsMedicationsHIVInformed consentExtensive involvementVirus BU.S. population
2003
Human Immunodeficiency Virus Infection with Human Granulocytic Ehrlichiosis Complicated by Symptomatic Lactic Acidosis
Springer SA, Altice FL. Human Immunodeficiency Virus Infection with Human Granulocytic Ehrlichiosis Complicated by Symptomatic Lactic Acidosis. Clinical Infectious Diseases 2003, 36: e162-e164. PMID: 12802782, DOI: 10.1086/374930.Peer-Reviewed Original ResearchConceptsHuman granulocytic ehrlichiosisSymptomatic hyperlactatemiaLactic acidosisNormal serum lactate levelsHuman immunodeficiency virus (HIV) infectionNucleoside reverse transcriptase inhibitorSymptomatic lactic acidosisImmunodeficiency virus infectionSerum lactate levelsHuman immunodeficiency virusReverse transcriptase inhibitorAcute coinfectionAntiretroviral therapyHIV infectionHepatic insultImmunodeficiency virusAppropriate treatmentVirus infectionLactate levelsFirst presentationGranulocytic ehrlichiosisPatientsHyperlactatemiaAcidosisInfection